FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease …
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease …
Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous …
The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …
The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost therapeutic intervention options …
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase …
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results …
Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev …
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than …
The US Food and Drug Administration’s (FDA’s) pilot scheme to expedite the review of US-made generic medicines is welcomed but …
France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the antibody-drug conjugate (ADC) pipeline …
Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand …
Wachtell, Lipton, Rosen & Katz and Kirkland & Ellis have emerged as the top mergers and acquisitions (M&A) legal advisers …
Goldman Sachs and Houlihan Lokey have emerged as the leading mergers and acquisitions (M&A) financial advisers in North America by …
A&O Shearman and CMS have emerged as the top legal advisers in terms of deal value and deal volume, respectively, …
AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to …